Gel containing Pirfenidone
The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.
1. A method for treating fibrotic lesions in a patient by administering to the patient a composition of pirfenidone gel consisting of:
(a) 2-12% pirfenidone;
(b) 0.4-1.2% of a viscous agent selected from the group consisting of Carbomer 940, Ultrex 10, cellulose derivatives, gums, and poloxamers;
(c) 10-30% of a solubilizer selected from the group consisting of N-methylpyrrolidone, ethyl alcohol, and propylene glycol;
(d) 5-15% of a non-ionic solubilizer;
(e) 0.2-1% of a conserving agent selected from the group consisting of diazolidinyl urea, iodopropynyl butylcarbamate, methylparaben, propylparaben, and combinations of these conserving agents;
(f) 0.4-1.2% of a neutralizer agent selected from the group consisting of primary, secondary and tertiary mono-, bi-, and triethanolamine aliphatic amines, and hydroxide alkaline metals; and
(g) water;
thereby treating the fibrotic lesions.
2. The method of claim 1 , wherein the composition is prepared by:
(a) mixing approximately 50% of the total water to be used with the viscous agent and allowing complete humectation of the viscous agent;
(b) mixing pirfenidone and the solubilizer separately and with agitation;
(c) dissolving separately the non-ionic solubilizer in approximately 25% of total water at approximately 40° C. and once dissolved, adding approximately 15% of the total water;
(d) adding the solution from part (c) to the mix from part (b), and agitating until homogenous;
(e) diluting the neutralizer agent in approximately 10% of the total water to be used, and agitating until homogenous; and
(f) combining the solutions of parts (a)-(e).
3. The method of claim 1 , wherein
the conserving agent is a combination of diazolidinyl urea and iodopropynyl butylcarbamate.
4. The method of claim 1 , wherein the viscous agent is Carbomer 940, the solubilizer is N-methylpyrrolidone, the conserving agent is diazolidinyl urea, and the neutralizer agent is triethanolamine.
5. The method of claim 1 , wherein the viscous agent is Carbomer 940, the solubilizer is N-methylpyrrolidone, the conserving agent is iodopropynyl butylcarbamate, and the neutralizer agent is triethanolamine.
6. The method of claim 1 , wherein at least one of the hydroxide alkaline metals is sodium hydroxide.
7. The method of claim 1 , wherein the viscous agent is Carbomer 940.
8. The method of claim 1 , wherein the viscous agent is Ultrex 10.
9. The method of claim 1 , wherein the solubilizer is N-methylpyrrolidone.
10. The method of claim 1 , wherein the solubilizer is propylene glycol.
11. The method of claim 1 , wherein the conserving agent is diazolidinyl urea.
12. The method of claim 1 , wherein the conserving agent is iodopropynyl butylcarbamate.
13. The method of claim 1 , wherein the conserving agent is methylparaben.
14. The method of claim 1 , wherein the conserving agent is propylparaben.
15. The method of claim 1 , wherein the neutralizer agent is triethanolamine.
16. The method of claim 1 , wherein the neutralizer agent is hydroxide alkaline metal.
17. The method of claim 1 , wherein the non-ionic solubilizer is macrogolglycerol hydroxystearate 40.
18. The method of claim 1 , wherein the method causes restoration of tissue with fibrotic lesions.
19. The method of claim 1 , wherein the composition of pirfenidone gel consists of 8% pirfenidone, 0.5% of the viscous agent, 20% of the solubilizer, 11.5% of the non-ionic solubilizer, 0.5% of the conserving agent, 0.5% of the neutralizer agent, and 59% of purified water.
20. The method of claim 1 , wherein the viscous agent is Carbomer 940, the solubilizer is N-methylpyrrolidone, the conserving agent is diazolidinyl urea and iodopropynyl butylcarbamate, and the neutralizer agent is triethanolamine.
21. The method of claim 1 , wherein the neutralizer agent is sodium hydroxide.
22. The method of claim 1 , wherein the administering comprises cutaneous administration.